Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255903 | 0.89 | BCL2 (0.46) | CTBP2ALDH1A1MEN1KMT2A | |
| SCHEMBL27550263 | 0.89 | PNMT (0.50) | ALDH1A1 | |
| SCHEMBL23276465 | 0.87 | CTBP2 (0.56) | CTBP2ALDH1A1KMT2A | |
| SCHEMBL1350536 | 0.87 | CTBP2 (0.61) | CTBP2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10488625 | 0.86 | NLRP3 (0.41) | — | |
| SCHEMBL10386674 | 0.85 | CYP1A2 (0.46) | CTBP2 | |
| SCHEMBL30544187 | 0.85 | CTBP2 (0.57) | CTBP2ALDH1A1 | |
| SCHEMBL18412078 | 0.85 | ALDH1A1 (0.46) | CTBP2ALDH1A1MEN1KMT2A | |
| SCHEMBL726784 | 0.85 | CTBP2 (0.57) | CTBP2ALDH1A1 | |
| SCHEMBL1149255 | 0.85 | TAAR1 (0.47) | CES2CES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003793-A | Polyamide-imide film and preparation method thereof | 株洲时代华昇新材料技术有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11622958-B2 | Bifunctional prodrugs | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (DE) | 2023-04-11 | — | — | US | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180311212-A1 | BIFUNCTIONAL PRODRUGS | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHS (DE) | 2018-11-01 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3368091-A1 | BIFUNCTIONAL PRODRUGS | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (DE) | 2018-09-05 | — | — | EP | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7635741-B2 | Curable polyacetylenes used as dielectrics in making microelectronics such as integrated circuits | DOW GLOBAL TECHNOLOGIES INC. | 2009-12-22 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1476416-A2 | MULTIFUNCTIONAL MONOMERS AND THEIR USE IN MAKING CROSS-LINKED POLYMERS AND POROUS FILMS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040053033-A1 | Multifunctional monomers and their use in making cross-linked polymers and porous films | NIU Q JASON (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2003068825-A2 | MULTIFUNCTIONAL MONOMERS AND THEIR USE IN MAKING CROSS-LINKED POLYMERS AND POROUS FILMS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-5670493-A | ANGIOGENESIS INHIBITORS | ADIR ET COMPAGNIE (FR) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CTBP2 1820/4885CES2 2890/4885CES1 2397/4885 |
| US-20180311212-A1 | BIFUNCTIONAL PRODRUGS | PAICS, FCGRT, ENTPD1 | CTBP2 2494/4885CES2 451/4885CES1 142/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTBP2 1931/4885CES2 2912/4885CES1 2406/4885 |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | CTBP2 3412/4885CES2 245/4885CES1 1631/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CTBP2 1808/4885CES2 2782/4885CES1 2370/4885 |
| US-11622958-B2 | Bifunctional prodrugs | PAICS, FCGRT, ENTPD1 | CTBP2 2494/4885CES2 451/4885CES1 142/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CTBP2 1820/4885CES2 2890/4885CES1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.